publication venue for
- Activation of Autophagy Protein, Rubicon, Causes Resistance To Transforming Growth Factor Beta (Tgf Beta)-Induced Apoptosis in Cirrhotic Livers. 56:257A. 2012-10-01
- Boceprevir (Boc) Combined With Peginterferon Alfa-2B/Ribavirin (P/Rbv) in Treatment-Naive Chronic Hcv Genotype 1 Patients With Compensated Cirrhosis: Sustained Virologic Response (Svr) and Safety Subanalyses From the Anemia Management Study. 56:216A. 2012-10-01
- Genome-Wide Association Study To Characterize Potential Determinants of Bilirubin Elevations in Hcv Patients Receiving the Hcv Ns3 Serine Protease Inhibitor Gs-9256. 56:585A-586A. 2012-10-01
- Incidentally Discovered Hcc (Ihcc) in Explant Liver- Clinical and Histopathologic Features and Outcome. 56:476A-477A. 2012-10-01
- Metabolic and Histological Effects of Liver Fat Accumulation in Patients With Nash. 56:894A. 2012-10-01
- Once Daily Sofosbuvir (Gs-7977) Plus Peg/Rbv: High Early Response Rates Are Maintained During Post-Treatment Follow-Up in Treatment-Naive Patients With Hcv Genotype 1, 4, and 6 Infection in the Atomic Study. 56:307A. 2012-10-01
- Relationship of Cytokeratin-18 With Clinical, Metabolic and Histological Parameters in Patients With Nonalcoholic Steatohepatitis (Nash). 56:900A-901A. 2012-10-01
- Sirtuin 1-Induced Autophagy Suppresses Ischemia/Reperfusion Injury To Mouse Liver. 56:1120A. 2012-10-01
- The Detrimental Effect of Patient's Geography From the Liver Transplant Center: Impact of Hpatitis C. 56:505A. 2012-10-01
- The Impact of Pre Transplant Transarterial Therapy in Hepatocellular Carcinoma. 56:458A-459A. 2012-10-01
- The Safety of Telaprevir in the Absence of Interferon And/Or Ribavirin: Analysis of On-Treatment Data From the Zenith Trial. 56:574A-575A. 2012-10-01
- Vx-222, Telaprevir and Ribavirin in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C: Results of the Zenith Study Interferon-Free Regimen. 56:308A. 2012-10-01
- Pegylated Interferon for Chronic Hepatitis C in Children Affects Growth and Body Composition: Results From the Pediatric Study of Hepatitis C (Peds-C) Trial. 56:523-531. 2012-08-01
- An Update On Treatment of Hepatitis C Virus Genotype 1 Infection and Viral Load Assessments Reply. 55. 2012-03-01
- Antiviral Effect of Sorafenib in Hcv Related Hepatocellular Carcinoma. 54:1422A. 2011-10-01
- Klatskin Tumor- Clinical Outcome and Prognostic Factors. 54:1372A. 2011-10-01
- Once-Daily Psi-7977 Plus Peg/Rbv in Treatment-Naive Patients With Hcv Gt1: Robust End of Treatment Response Rates Are Sustained Post-Treatment. 54:472A-473A. 2011-10-01
- Sustained Virologic Response (Svr) in American Naive Mono-Infected Chronic Hepatitis C (Chc) Patients (Pts) Treated With Peginterferon Alfa (Pegifn Alpha) Plus Ribavirin (Rbv): Final Analysis of the Large, Multinational Real-World Prophesys Database. 54:865A-866A. 2011-10-01
- Sustained Virologic Response Rates and Viral Resistance Profiles Were Similar in Patients Treated With a Telaprevir-Based Regimen Regardless of Liver Fibrosis Stage. 54:1348A. 2011-10-01
- Transarterial Chemoembolization (Tace) for Hepatocellular Carcinoma - Comparison Between Conventional Technique and Drug Eluting Beads. 54:1411A. 2011-10-01
- Vx-222/Telaprevir in Combination With Peginterferon-Alfa-2a and Ribavirin in Treatment-Naive Genotype 1 Hcv Patients Treated for 12 Weeks: Zenith Study, Svr12 Interim Analysis. 54:1435A. 2011-10-01
- Antiviral Activity of the Hepatitis C Virus Polymerase Inhibitor Filibuvir in Genotype 1 Infected Patients. 54:50-59. 2011-07-01
- Peginterferon With Or Without Ribavirin Has Minimal Effect On Quality of Life, Behavioral/Emotional, and Cognitive Outcomes in Children. 53:1468-1475. 2011-05-01
- Clinical Synergy of An Anti-Hcv Nucleoside Analog With Soc: Viral Kinetics of Psi-7977 With Society. 52:1861. 2010-10-01
- Evaluating Progression of Liver Disease From Paired Liver Biopsies in Children With Chronic Hepatitis C Infection (Hcv). 52:1913. 2010-10-01
- Genotype-Specific Predictors of Early Viral Clearance Following Treatment With Peginterferon Alfa-2a (40Kd) (Pegifn Alpha-2A) Plus Ribavirin (Rbv): Multiple Logistic Regression Analysis From the Large Multinational Prophesys Cohorts. 52:1002. 2010-10-01
- Hepatic Tgf Beta 1 and Ctgf Over-Expression in Rhesus Rotavirus-Induced Neonatal Murine Model of Biliary Atresia. 52:1469. 2010-10-01
- Incidence of Hepatocellular Carcinoma in Florida: Distribution in Racial Subpopulations. 52:1750. 2010-10-01
- Overexpression of Atg4B and Beclin-1 Enhances Liver Mitochondrial-Autophagy and Prevents the Age-Associated Ischemia/Reperfusion Injury To Mouse Liver. 52:91. 2010-10-01
- Predictors of Relapse in Genotype 3 Infected Chronic Hcv Patients Who Achieve Rapid Virologic Response. 52:991. 2010-10-01
- Safety and Virologic Response Rates in Patients With History of Injection Drug Use (Idu): Pooled Analysis of Data From Four Randomized Phase III Studies of Peginterferon Alfa-2a (40Kd) Plus Ribavirin (Rbv). 52:1001. 2010-10-01
- Telaprevir in Combination With Peginterferon Alfa2a and Ribavirin for 24 Or 48 Weeks in Treatment-Naive Genotype 1 Hcv Patients Who Achieved An Extended Rapid Viral Response: Final Results of Phase 3 Illuminate Study. 52:LB-2. 2010-10-01
- The Impact of Preservation Injury On Accelerated Hepatitis C Recurrence After Liver Transplantation. 52:2. 2010-10-01
- The Impact of Transarterial Therapy in Recurrent Hepatocellular Carcinoma After Liver Transplant. 52:1753. 2010-10-01
- Epigenetic Regulation of Hepatic Endoplasmic Reticulum Stress Pathways in the Ethanol-Fed Cystathionine Beta Synthase-Deficient Mouse. 51:932-941. 2010-03-01
- Betaine for Nonalcoholic Fatty Liver Disease: Results of a Randomized Placebo-Controlled Trial. 50:1818-1826. 2009-12-01
- A Randomized Controlled Trial of the Efficacy, Tolerability, and Safety of Prophylactic Treatment With Peginterferon Alfa-2a Plus Ribavirin After Orthotopic Liver Transplantation (Olt) for Hepatitis C: the Phoenix Study. 50:506. 2009-10-01
- Anti-Hepatitis C Viral Activities By Inducible Stat1 Activation. 50:1428. 2009-10-01
- Changes in Body Mass Index and Body Composition in Children Treated With Peginterferon for Chronic Hepatitis C in the Peds-C Trial. 50:708. 2009-10-01
- Early Changes in Viral Load Predict Sustained Viral Response (Svr) in the Peds C Trial. 50:240. 2009-10-01
- Efficacy and Safety Results of Albinterferon Alfa-2B in Combination With Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 2 Or 3. 50:1567. 2009-10-01
- Epigenetic Regulation of Homeobox Genes in Liver Cancer. 50:1814. 2009-10-01
- Fenofibrate Improves Liver Biochemistries in Primary Biliary Cirrhosis. 50:1503. 2009-10-01
- Hepatitis B Viral Dna Seldom Present in the Transplant Liver From Anti-Hbc-Positive Donors. 50:530. 2009-10-01
- Hepatitis C Drug Development At a Crossroads. 50:997-999. 2009-10-01
- Identifying Hcv Genotype 2/3 Patients Who Could Receive a 16-Week Abbreviated Course of Peginterferon Alfa-2a (40Kd) Plus Ribavirin. 50:35. 2009-10-01
- Insulin Resistance and Hepatic Steatosis Are Both Independently Associated With Advanced Hepatic Fibrosis in Chronic Hepatitis C Infection: Analysis of the Achieve 1 and Achieve 2/3 Cohorts. 50:1622. 2009-10-01
- Longitudinal Prospective Comparison of Fibrosure and Fibroscan in Relation To Virologic Response in a Phase III Study of Albinterferon Alfa-2B and Ribavirin in Treatment Naive Chc Patients. 50:1084. 2009-10-01
- Peginterferon Alfa-2a With Or Without Ribavirin Results in Minimal Effect On Quality of Life, Emotional, and Cognitive Outcomes: Results of the Peds-C Trial. 50:238. 2009-10-01
- Similar Rates of Interstitial Findings On Chest X-Ray in Hcv Patients Treated With Albinterferon Alfa-2B Or Peginterferon Alfa-2a. 50:1572. 2009-10-01
- Sustained Virologic Response 15 Independently Associated With Improvement in Insulin Resistance in Genotype 1, But Not Genotype 2/3, Chronic Hcv Patients. 50:117. 2009-10-01
- A Phase III Study of the Safety and Efficacy of Viramidine Versus Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C: Viser1 Results. 50:717-726. 2009-09-01
- Protein Or Amino Acid Deprivation Differentially Regulates the Hepatic Forkhead Box Protein a (Foxa) Genes Through An Activating Transcription Factor-4-Independent Pathway. 50:282-290. 2009-07-01
- Single Nucleotide Polymorphism-Mediated Translational Suppression of Endoplasmic Reticulum Mannosidase I Modifies the Onset of End-Stage Liver Disease in Alpha1-Antitrypsin Deficiency. 50:275-281. 2009-07-01
- Retreating Chronic Hepatitis C With Daily Interferon Alfacon-1/Ribavirin After Nonresponse To Pegylated Interferon/Ribavirin: Direct Results. 49:1838-1846. 2009-06-01
- Translocation of Iron From Lysosomes Into Mitochondria Is a Key Event During Oxidative Stress-Induced Hepatocellular Injury. 48:1644-1654. 2008-11-01
- Antiviral Activity of the Hcv Nucleoside Polymerase Inhibitor R7128 in Hcv Genotype 2 and 3 Prior Non-Responders: Interim Results of R7128 1500Mg Bid With Peg-Ifn and Ribavirin for 28 Days. 48:1024A. 2008-10-01
- Hbv Recurrence Rate Post-Liver Transplantation (Olt) and Associated Factors: Results of the Nih-Hbv-Olt Study. 48:571A-572A. 2008-10-01
- Hepatocellular Carcinoma (Hcc) Is the Main Indication for Liver Transplantation (Olt) Among Hbv Patients in the Era of Nucleos/Tide Analogue Therapies. 48:946A-947A. 2008-10-01
- Hepatocyte Growth Factor and Granulocyte-Colony Stimulating Factor Guide the Growth, Motility and Survival of Oval Cell-Derived Rat Liver Cancer Cell Lines. 48:496A-497A. 2008-10-01
- High Relapse Rate Seen At Week 72 for Patients Treated With R1626 Combination Therapy. 48:1349-1350. 2008-10-01
- High-Dose Betaine Treatment Does Not Positively Influence Second Hit Mechanisms in Nash. 48:817A. 2008-10-01
- Hsp90 Inhibition Decreases Human Hepatocellular Cancer Xenograft Growth. 48:975A. 2008-10-01
- Impact of Antiviral Resistance Mutations in the Hepatitis B Virus (Hbv) P Gene On Hbv S Gene and Implications for Liver Transplant (Olt) Patients. 48:699A-700A. 2008-10-01
- Impaired Autophagy Contributes To Resistance of Cirrhotic Liver-Derived Hepatocytes To Transforming Growth Factor Beta (Tgf Beta)-Induced Apoptosis. 48:916A. 2008-10-01
- Improved Outcomes in Patients With Hepatitis C With Difficult-To-Treat Characteristics: Randomized Study of Higher Doses of Peginterferon Alpha-2a and Ribavirin. 48:1033-1043. 2008-10-01
- Longitudinal Incidence of Liver Complications and Initiation of Antiviral Therapy Among Hcv-Infected Patients Enrolled in a Managed Care Organization (Mco). 48:1127A. 2008-10-01
- Peginterferon With Or Without Ribavirin for Chronic Hepatitis C in Children and Adolescents: Final Results of the Peds-C Trial. 48:418A. 2008-10-01
- Potent Antiviral Response To the Hcv Nucleoside Polymerase Inhibitor R7128 for 28 Days With Peg-Ifn and Ribavirin: Subanalysis By Race/Ethnicity, Weight and Hcv Genotype. 48:1160A. 2008-10-01
- Using Immune Functional Assay To Differentiate Acute Cellular Rejection From Recurrent Hepatitis C in Liver Transplant Patients. 48:555A. 2008-10-01
- Murine Cirrhosis Induces Hepatocyte Epithelial Mesenchymal Transition and Alterations in Survival Signaling Pathways. 48:909-919. 2008-09-01
- Children With Chronic Hepatitis C: What Future? Reply. 48:692. 2008-08-01
- R1626 Plus Peginterferon Alfa-2a Provides Potent Suppression of Hepatitis C Virus Rna and Significant Antiviral Synergy in Combination With Ribavirin. 48:385-397. 2008-08-01
- Location Is Everything: the Liver Stem Cell Niche. 47:1810-1812. 2008-06-01
- Impaired Autophagy: a Mechanism of Mitochondrial Dysfunction in Anoxic Rat Hepatocytes. 47:1725-1736. 2008-05-01
- Tis21 Negatively Regulates Hepatocarcinogenesis By Disruption of Cyclin B1-Forkhead Box M1 Regulation Loop. 47:1533-1543. 2008-05-01
- Connective Tissue Growth Factor With a Novel Fibronectin Binding Site Promotes Cell Adhesion and Migration During Rat Oval Cell Activation. 47:996-1004. 2008-03-01
- Pathology of Chronic Hepatitis C in Children: Liver Biopsy Findings in the Peds-C Trial. 47:836-843. 2008-03-01
- Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.. 42. 2005
- Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect.. 38:859-868. 2003
- Mouse A6-positive hepatic oval cells also express several hematopoietic stem cell markers.. 37. 2003